RxDoctor Payments Data

Denise Casper, DO

Family Medicine · Decatur, TXNPI 1477504173

Payments from drug & device makers

$5,702in general payments, 2019–2025

Across 330 payments — averaging $17.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$792
  • AstraZeneca$722
  • Novo Nordisk$629
  • Lilly USA, LLC$428
  • Boehringer Ingelheim$339
  • Pfizer$335
  • plus $2K from 47 others

What the payments were for

  • Food & beverage$5,60898%
  • Education$942%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,702 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$216,701
Medicare patients
373
Services billed
8,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide139$222,362
JardianceEmpagliflozin117$101,366
EliquisApixaban93$90,697
MounjaroTirzepatide43$56,947
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$54,920
FarxigaDapagliflozin Propanediol45$34,529
MyrbetriqMirabegron39$26,844
ProliaDenosumab11$18,579
XareltoRivaroxaban22$16,832
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$14,837
VascepaIcosapent Ethyl24$12,806
Tresiba Flextouch U-200Insulin Degludec13$12,361
JanuviaSitagliptin Phosphate11$12,138
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$11,541
BelsomraSuvorexant21$9,049

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$629$222,362139 claims
Boehringer IngelheimJardiance, Combivent Respimat$339$107,648129 claims
PfizerEliquis$335$90,69793 claims
Lilly USA, LLCMounjaro$428$56,94743 claims
GSKTrelegy Ellipta$318$54,92041 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$722$53,02676 claims
Astellas Pharma US IncMyrbetriq$328$26,84439 claims
MerckJanuvia, Belsomra$93$21,18732 claims
AmgenProlia$105$18,57911 claims
Johnson & JohnsonXarelto$71$16,83222 claims
AbbVieLinzess, Synthroid$792$8,20338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Decatur

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →